Watson, Geoffrey A. http://orcid.org/0000-0003-1962-7893
Veitch, Zachary W.
Shepshelovich, Daniel
Liu, Zhihui Amy
Spreafico, Anna http://orcid.org/0000-0002-3034-3042
Abdul Razak, Albiruni R.
Bedard, Philippe L.
Siu, Lillian L. http://orcid.org/0000-0002-3500-0540
Minasian, Lori
Hansen, Aaron R. http://orcid.org/0000-0002-2363-8707
Article History
Received: 20 February 2022
Revised: 28 June 2022
Accepted: 14 July 2022
First Online: 25 August 2022
Ethics approval and consent to participate
: This protocol was approved by the Princess Margaret Cancer Centre Research Ethics Board (REB) and conformed to the Helsinki Declaration. All participants provided written informed consent prior to study enrolment.
: GW has received travels grants from BMS and Abbvie, and received honoraria from Pfizer. ZWV has received an honorarium from Pfizer and Genomic Health. He has also served on an advisory board for Genomic Health. PLB reports grants from Bristol-Myers-Squibb, Sanofi, Genentech/Roche Novartis, GlaxoSmithKline, Nektar Therapeutics, Merck, Lilly, Servier, PTC Therapeutics, Seattle Genetics, Mersana outside the submitted work; and Uncompensated advisory boards for Bristol-Myers-Squibb, Sanofi, Pfizer, Genentech/Roche. LLS reports compensated consultancy/advisory board participation for Merck, Pfizer, Celgene, AstraZeneca/Medimmune, Morphosys, Roche, GeneSeeq, Loxo, Oncorus, Symphogen, Seattle Genetics, Glaxo-Smith-Kline, Voronoi, Treadwell Therapeutics, Arvinas, Tessa and Navire; and reports institutional support for clinical trials conduct from Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Celgene, Astellas, Bayer, AbbVie, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks and Avid. Spouse hold stock in Agios and Treadwell Therapeutics. ARH reports institutional support for clinical trials to conduct by Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Astellas and Bayer; and compensated consulting/advisory boards for AstraZeneca, Merck and GlaxoSmithKline. ARAR has received research funding from Roche, Genentech, Eli Lilly, Merck, Boehringer-Ingelheim, Novartis, AbbVie, Deciphera, Karyopharm, AstraZeneca, Medimmune, Blueprint, Bristol-Myers Squibb, GSK, Entremed/Casi Pharmaceuticals, Adaptimmune and BetaCat. He also has also served the advisory board for Eli Lilly, Merck, Adaptimmune, Boehringer-Ingelheim. AS has served as an advisory board consultant for Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), Oncorus (compensated), Janssen (compensated). She has also received research funding from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma, GSK. DS, ZAL, LM report no competing interests.
: Not applicable.